Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 1.00 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.57 |
| ▸ | KIF11 | P52732 | 2/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.50 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30704691 | 1.00 | PARP1 (1.00) | PARP1CSNK2A1DYRK1AKIF11ROCK2 | |
| SCHEMBL2691509 | 0.95 | PARP1 (0.90) | PARP1CSNK2A1DYRK1AKIF11ROCK2 | |
| SCHEMBL10134619 | 0.90 | PARP1 (0.81) | PARP1CSNK2A1DYRK1AKIF11ROCK2 | |
| SCHEMBL16377295 | 0.87 | PARP1 (0.76) | PARP1CSNK2A1DYRK1AKIF11ROCK2 | |
| SCHEMBL30172793 | 0.85 | PARP1 (0.74) | PARP1CSNK2A1DYRK1AKIF11ROCK2 | |
| SCHEMBL4972014 | 0.84 | PARP1 (1.00) | PARP1CSNK2A1DYRK1AROCK2ROCK1 | |
| SCHEMBL10135321 | 0.83 | PARP1 (0.78) | PARP1CSNK2A1ROCK2ROCK1GSK3B | |
| SCHEMBL10134618 | 0.82 | PARP1 (0.70) | PARP1CSNK2A1DYRK1AROCK2ROCK1 | |
| SCHEMBL25293367 | 0.82 | PARP1 (1.00) | PARP1CSNK2A1DYRK1AKIF11KMT2A | |
| SCHEMBL628532 | 0.80 | PARP1 (0.67) | PARP1CSNK2A1DYRK1AKIF11GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383624-B2 | Cargo delivery system and composition comprising the same | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-08-12 | — | — | US | disclosed |
| CN-117263934-A | Preparation method of 5H-benzo [ c ] [1,6] naphthyridine-6-ketone derivative | 上海凌凯医药科技有限公司 | 2023-12-22 | — | — | CN | disclosed |
| WO-2023126951-A1 | INHIBITORS OF AUTOPHAGY-RELATED PROTEIN-PROTEIN INTERACTIONS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023126951-A1 | INHIBITORS OF AUTOPHAGY-RELATED PROTEIN-PROTEIN INTERACTIONS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-07-06 | — | — | WO | disclosed |
| US-20230190938-A1 | NOVEL CARGO DELIVERY SYSTEM AND COMPOSITION COMPRISING THE SAME | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2023-06-22 | — | — | US | disclosed |
| US-20230190938-A1 | NOVEL CARGO DELIVERY SYSTEM AND COMPOSITION COMPRISING THE SAME | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2023-06-22 | — | — | US | disclosed |
| US-11071727-B2 | Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2021-07-27 | — | — | US | disclosed |
| US-20190231759-A1 | THERAPEUTIC TARGETING OF PROTEOLYTIC CLEAVAGE OF THE MIXED LINEAGE LEUKEMIA GENE PRODUCT (MLL1) BY TASPASE1 USING KINASE INHIBITORS | NORTHWESTERN UNIVERSITY (US) | 2019-08-01 | — | — | US | disclosed |
| US-9176064-B2 | Bisubstrate fluorescent probes for protein kinase CK2 | UNIVERSITY OF TARTU (EE) | 2015-11-03 | — | — | US | disclosed |
| US-9176064-B2 | Bisubstrate fluorescent probes for protein kinase CK2 | UNIVERSITY OF TARTU (EE) | 2015-11-03 | — | — | US | disclosed |
| WO-2009097014-A2 | THERAPEUTIC KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
| EP-2061765-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | Cylene Pharmaceuticals, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-04-23 | — | — | US | disclosed |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-04-23 | — | — | US | disclosed |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-04-23 | — | — | US | disclosed |
| US-20090093465-A1 | THERAPEUTIC KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093465-A1 | THERAPEUTIC KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093465-A1 | THERAPEUTIC KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2008028168-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008028168-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190231759-A1 | THERAPEUTIC TARGETING OF PROTEOLYTIC CLEAVAGE OF THE MIXED LINEAGE LEUKEMIA GENE PRODUCT (MLL1) BY TASPASE1 USING KINASE INHIBITORS | MLLT1, TASP1, MLLT3 | PARP1 317/4885CSNK2A1 38/4885DYRK1A 1713/4885 |
| US-20230190938-A1 | NOVEL CARGO DELIVERY SYSTEM AND COMPOSITION COMPRISING THE SAME | ATG7, SQSTM1, BECN1 | PARP1 2432/4885CSNK2A1 956/4885DYRK1A 2472/4885 |
| US-12383624-B2 | Cargo delivery system and composition comprising the same | ATG7, SQSTM1, BECN1 | PARP1 2026/4885CSNK2A1 1104/4885DYRK1A 2481/4885 |
| US-20090093465-A1 | THERAPEUTIC KINASE MODULATORS | PACSIN2, CKS1B, CSNK1A1 | PARP1 1797/4885CSNK2A1 6/4885DYRK1A 427/4885 |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | PACSIN2, TNKS, PARP1 | PARP1 3/4885CSNK2A1 24/4885DYRK1A 502/4885 |
| US-11071727-B2 | Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors | MLLT1, TASP1, MLLT3 | PARP1 317/4885CSNK2A1 38/4885DYRK1A 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.